Aromatase inhibitors versus tarnoxifen as adjuvant therapy for postmenopausal women with estrogen receptor positive breast cancer: meta-analyses of randomized trials of monotherapy and switching strategies

Similar Items

• Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen
  by: Dowsett, M, et al.
  Published: (2009)
• Aromatase Inhibitors (AIs) Versus Not (Placebo/Observation) as Late Extended Adjuvant Therapy for Postmenopausal Women with Early Stage Breast Cancer (BC): Overviews of Randomized Trials of AIs after similar to 5 Years of Tamoxifen
  by: Goss, P, et al.
  Published: (2009)
• Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer
  by: Swaathi Jayaraman, et al.
  Published: (2020-05-01)
• Cost-effectiveness of Tamoxifen, Aromatase Inhibitor, and Switch Therapy (Adjuvant Endocrine Therapy) for Breast Cancer in Hormone Receptor Positive Postmenopausal Women in India
  by: Butani D, et al.
  Published: (2021-11-01)
• Aromatase Inhibitors Reduce the Expression of a Hypoxia Metagene in Oestrogen Receptor Positive Breast Cancer in Postmenopausal Women.
  by: Ghazoui, Z, et al.
  Published: (2009)